ALNYLAM PHARMACEUTICALS, INC.
Close on Oct 19, 2026
- Market cap
- $32.26B
- P/E (TTM)
- 43.4
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $1.17B | $1.51 | $1.99 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $1.10B | $0.82 | $1.25 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $1.25B | $1.84 | $2.90 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | Before market open | $773.69M | $-0.51 | $0.32 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | Before market open | $439.72M | $-1.10 | $-0.77 |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | Before market open | $750.53M | $1.15 | $1.74 |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 4, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Feb 23, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Apr 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Non-GAAP R&D and SG&A expensesnon-GAAP | Full-year 2026 | $2.70B to $2.80B | New |
| Net product revenues growth vs. 2025 at constant exchange ratesnon-GAAP | Full-year 2026 | 64% to 77% growth | New |
| Net product revenues growth vs. 2025 at currency exchange rates as of December 31, 2025 | Full-year 2026 | 64% to 77% growth | New |
| Total Rare net product revenues (GIVLAARI, OXLUMO) | Full-year 2026 | $500.00M to $600.00M | Lowered |
| Total net product revenues | Full-year 2026 | $4.90B to $5.30B | Raised |
| Net revenues from collaborations and royalties | Full-year 2026 | $400.00M to $500.00M | Lowered |
| Total TTR net product revenues (AMVUTTRA, ONPATTRO) | Full-year 2026 | $4.40B to $4.70B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Alnylam Pharmaceuticals filed with the SEC
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Results of operations · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress
Results of operations · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
Results of operations · EX-99.1 to Form 8-K
Alnylam Launches “ Alnylam 2030 ” Strategy to Drive Next Era of Growth and Patient Impact
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Other events · EX-99.1 to Form 8-K
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
Other events · EX-99.2 to Form 8-K
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
Results of operations · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides
Results of operations · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for
Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for
Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Updates to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Proposed Offering of
Other events · EX-99.1 to Form 8-K
Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes
Other events · EX-99.2 to Form 8-K
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces FDA Approval of AMVUTTRA
Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces 3-Month Extension of Review Period for New Drug
Other events · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
Results of operations · EX-99.1 to Form 8-K
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Alnylam Announces Planned CEO Leadership Transition
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K